Publications by authors named "Kevin Zikaras"
Article Synopsis
- - The study evaluates the safety and effectiveness of a T cell receptor fusion construct, gavo-cel, in patients with mesothelin-expressing solid tumors who did not respond to previous treatments, participating in a phase 1/2 trial.
- - The recommended phase 2 dose (RP2D) was set at 1 × 10^6 cells per m² after lymphodepletion, with some serious toxicities observed, including pneumonitis and bronchioalveolar hemorrhage.
- - Initial results show a 20% overall response rate and a 70% 6-month overall survival rate, suggesting gavo-cel's potential effectiveness but also highlighting concerns about its safety and the need for
